Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
Por:
Alcaraz, A, Rodriguez-Antolin, A, Carballido-Rodriguez, J, Castro-Diaz, D, Medina-Polo, J, Fernandez-Gomez, JM, Ficarra, V, Palou, J, Roca, JPD, Angulo, JC, Esteban-Fuertes, M, Cozar-Olmo, JM, Perez-Leon, N, Molero-Garcia, JM, Ledesma, AFP, Brenes-Bermudez, FJ, Manasanch, J
Publicada:
29 sep 2021
Resumen:
In a subset analysis of data from a 6-month, multicenter, non-interventional study, we compared change in symptoms and quality of life (QoL), and treatment tolerability, in men with moderate to severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving tamsulosin (TAM, 0.4 mg/day) or the hexanic extract of Serenoa repens (HESr, 320 mg/day) as monotherapy. Symptoms and QoL were assessed using the IPSS and BII questionnaires, respectively. Patients in the treatment groups were matched using two statistical approaches (iterative and propensity score matching). Within the iterative matching approach, data was available from a total of 737 patients (353 TAM, 384 HESr). After 6 months, IPSS scores improved by a mean (SD) of 5.0 (4.3) points in the TAM group and 4.5 (4.7) points in the HESr group (p = 0.117, not significant). Improvements in QoL were equivalent in the two groups. TAM patients reported significantly more adverse effects than HESr patients (14.7% vs 2.1%; p < 0.001), particularly ejaculation dysfunction and orthostatic hypotension. These results show that HESr is a valid treatment option for men with moderate/severe LUTS/BPH; improvements in urinary symptoms and QoL were similar to those observed for tamsulosin, but with considerably fewer adverse effects.
Filiaciones:
Alcaraz, A:
Univ Barcelona, Hosp Clin, Urol Dept, IDIBAPS, Barcelona, Spain
Rodriguez-Antolin, A:
Hosp Univ 12 Octubre, Inst Invest I 12, Res Grp Mens Integral Hlth, Urol Dept, Madrid, Spain
Carballido-Rodriguez, J:
Hosp Univ Puerta Hierro Majadahonda, Urol Dept, Madrid, Spain
Castro-Diaz, D:
Hosp Univ Canarias, Urol Dept, Tenerife, Spain
Medina-Polo, J:
Hosp Univ 12 Octubre, Inst Invest I 12, Res Grp Mens Integral Hlth, Urol Dept, Madrid, Spain
Fernandez-Gomez, JM:
Hosp Univ Cent Asturias, Urol Dept, Oviedo, Spain
Ficarra, V:
Univ Messina, Urol Dept, Messina, Italy
Palou, J:
Autonoma Univ Barcelona, Fundacio Puigvert, Urol Dept, Barcelona, Spain
Roca, JPD:
Autonoma Univ Barcelona, Fundacio Puigvert, Urol Dept, Barcelona, Spain
Angulo, JC:
Hosp Univ Getafe, Urol Dept, Madrid, Spain
Esteban-Fuertes, M:
Hosp Nal Paraplej, Urol Dept, Toledo, Spain
Cozar-Olmo, JM:
Hosp Univ Virgen Nieves, Urol Dept, Granada, Spain
Perez-Leon, N:
Gran Sol Primary Care Ctr, Badalona, Spain
Molero-Garcia, JM:
San Andres Primary Care Ctr, Madrid, Spain
Ledesma, AFP:
Menasalbas Primary Care Ctr, Toledo, Spain
Brenes-Bermudez, FJ:
SEMERGEN Nefro Urol Working Grp, Barcelona, Spain
Manasanch, J:
Pierre Fabre Iber SA, Barcelona, Spain
Green Published, gold
|